Pricing Log in Create free account

Metagenomi Therapeutics, Inc. (MGX) vs TransCode Therapeutics Inc. (RNAZ)

Metagenomi Therapeutics, Inc. and TransCode Therapeutics Inc. are both Biotechnology companies. Metagenomi Therapeutics, Inc. and TransCode Therapeutics Inc. are of similar size ($27.6M and $25.6M). TransCode Therapeutics Inc. has the higher net margin (0.00% vs −689.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, TransCode Therapeutics Inc. leads on 7 and Metagenomi Therapeutics, Inc. on 5.

Valuation

Metric MGX RNAZ Biotechnology median
P/E n/m n/m 10.60
P/S 1.94 n/m 9.40
P/B 0.23 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.66 0.11 0.66
EV/Sales (4.72) n/m 9.02
Earnings yield (355.71%) (3,354.19%) (32.88%)
Free cash flow yield (325.47%) (1,565.69%) (23.13%)

Profitability

Metric MGX RNAZ Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (741.58%) 0.00% 0.00%
Net margin (689.20%) 0.00% 0.00%
Free cash flow margin (632.67%) 0.00% 0.00%
Return on equity (60.61%) 429.61% (51.96%)
Return on assets (41.91%) (58.12%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MGX RNAZ Biotechnology median
Revenue growth (TTM) (59.84%) — 6.76%
EPS growth (last fiscal year) 0.00% 96.02% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric MGX RNAZ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.50 1.97 4.97
Net debt to EBITDA 1.71 0.64 1.01

Dividend

Metric MGX RNAZ Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MGX RNAZ Biotechnology median
Market cap 27.60m 25.57m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack